Lab bone marrow model grown from patient cells successfully tests how the individual will respond to platelet-boosting treatments
For platelets, small blood cells responsible for clotting, balance is key: too many increases the risk of blood clots, while too few can lead to uncontrolled bleeding. One way of treating inherited thrombocytopenias, genetic disorders characterised by low platelet counts, is to boost megakaryocytes, platelet-producing cells in the bone marrow. Drugs like eltrombopag act as mimics of thrombopoietin, a protein that stimulates megakaryocyte production. Unfortunately, patients suffering from seemingly the same conditions respond differently to these treatments. To investigate this, scientists designed a laboratory model of human bone marrow (pictured), made of silk proteins and megakaryocytes (in red) derived from patient cells. Tests showed that how successfully eltrombopag increased platelet counts in this miniature system strongly correlated with the patients’ actual response to treatment. In the future, such models could help assess which treatments should be most effective for different patients, as well as facilitate further study and drug development.
BPoD stands for Biomedical Picture of the Day. Managed by the MRC London Institute of Medical Sciences the website aims to engage everyone, young and old, in the wonders of biomedicine. Images are kindly provided for inclusion on this website through the generosity of scientists across the globe.
BPoD is also available in Catalan at www.bpod.cat with translations by the University of Valencia.